Remove Acquisition Remove Avalon Remove Invest
article thumbnail

After Investing, GSK to Buy Out Celiac Drug Developer Sitari Pharma

Xconomy

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56
article thumbnail

AnaptysBio Sets Estimated IPO Pricing Range

socalTECH

AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. as early as Thursday.

Pricing 100
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Core Innovation Capital Sets Up Shop In LA

socalTECH

According to Core Innovation Capital , it has moved its offices to Los Angeles from New York City, to be closer to potential investments in its focus area of funding companies serving underbanked consumers in America. The fund has not yet announced local investments, but has been actively talking to companies fitting its investment profile.

Capital 174
article thumbnail

AnaptysBio Up Slightly In IPO

socalTECH

AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. Anaptys priced its IPO on Wednesday night at $15.00 per share, at the midpoint of its $14.00 estimated IPO range, and closed the day at $17.00 READ MORE>>.

Avalon 100